You are here: Industry Insights > CARSGEN

News List

CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA prnasia
January 11, 2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors...
With Diversified CAR-T Products in Hand, CARSGEN Applied for IPO in Hong Kong, S.A.R., China to Challenge the Treatment of Solid Tumor PharmaSources/Chuxin
July 09, 2021
On June 18, CARSGEN Therapeutics, a pioneer in the field of CAR-T cell therapy, officially listed on the Hong Kong, S.A.R., China Stock Exchange, offering 94.747 million shares, priced at HK $32.80 per share, raising a net of about HK $2.94 billion.
CARsgen Therapeutics officially listing on HKEX prnasia
June 21, 2021
CARsgen Therapeutics Holdings Limited announced that the Company's Shares have been traded on the Main Board of The Stock Exchange of Hong Kong, S.A.R., China Limited under the stock code "2171.HK".
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs prnasia
January 06, 2020
In the near future, CARsgen aims to submit several INDs, BLAs to US FDA, China NMPA and other regulatory agencies for our advanced CAR-T cell programs. We are delighted to have Dr. Fan joined, together with more and more global top talents to deliver our
CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody En-CPhI.CN
December 10, 2019
CARsgen Therapeutics, a clinical-stage biopharmaceutical company committed to discovering and developing a combined platform of Chimeric Antigen Receptor T (CAR-T) cell therapies ...
CARsgen Presents CAR-Claudin18.2-T Data at 2018 CAR-TCR Summit pharmafocusasia
September 10, 2018
BOSTON, Sept. 8, 2018 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, presented its preliminary clinical data of a first-in-class CAR-Claudin18.2 T cell trial fo
CARsgen Completed $60 Million Pre-C Financing Framework Agreements biospace
March 05, 2018
CARsgen Therapeutics today announces it has entered into a Pre-C financing framework agreement with receiving $60M equity investment from existing and new investors.
China based CARsgen gets $60M equity investment for CAR-T research biospectrumasia
March 05, 2018
The funds will be used in support of Investigational New Drug submissions of several CAR-T therapeutics and Next-generation CAR-T research.